AUTHOR=Rossi Ernesto , Maiorano Brigida Anna , Pagliara Monica Maria , Sammarco Maria Grazia , Dosa Tommaso , Martini Maurizio , Rindi Guido , Bria Emilio , Blasi Maria Antonietta , Tortora Giampaolo , Schinzari Giovanni 

TITLE=Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

JOURNAL=Frontiers in Oncology

VOLUME=9

YEAR=2019

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.00232

DOI=10.3389/fonc.2019.00232

ISSN=2234-943X

ABSTRACT=<p>Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.</p>